Scheltens P - Search Results

1

Variability of CSF Alzheimer's disease biomarkers: implications for clinical practice.

Vos SJ, Visser PJ, Verhey F, Aalten P, Knol D, Ramakers I, Scheltens P, Rikkert MG, Verbeek MM, Teunissen CE. Vos SJ, et al. Among authors: scheltens p. PLoS One. 2014 Jun 24;9(6):e100784. doi: 10.1371/journal.pone.0100784. eCollection 2014. PLoS One. 2014. PMID: 24959687 Free PMC article.

2

Operational definitions for the NINDS-AIREN criteria for vascular dementia: an interobserver study.

van Straaten EC, Scheltens P, Knol DL, van Buchem MA, van Dijk EJ, Hofman PA, Karas G, Kjartansson O, de Leeuw FE, Prins ND, Schmidt R, Visser MC, Weinstein HC, Barkhof F. van Straaten EC, et al. Among authors: scheltens p. Stroke. 2003 Aug;34(8):1907-12. doi: 10.1161/01.STR.0000083050.44441.10. Epub 2003 Jul 10. Stroke. 2003. PMID: 12855825

3

Biomarkers for Alzheimer's disease. Which way to go?

Teunissen CE, Scheltens P. Teunissen CE, et al. Among authors: scheltens p. Neurobiol Aging. 2004 Jul;25(6):695-6. doi: 10.1016/j.neurobiolaging.2003.08.013. Neurobiol Aging. 2004. PMID: 15165690 No abstract available.

4

Memantine in moderate-to-severe Alzheimer disease evidence and ethics based?

Rikkert MG, Dekkers WJ, Scheltens P, Verhey F. Rikkert MG, et al. Among authors: scheltens p. Alzheimer Dis Assoc Disord. 2004 Jan-Mar;18(1):47-8; author reply 48. doi: 10.1097/00002093-200401000-00010. Alzheimer Dis Assoc Disord. 2004. PMID: 15195464 No abstract available.

5

Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment.

Korf ES, Wahlund LO, Visser PJ, Scheltens P. Korf ES, et al. Among authors: scheltens p. Neurology. 2004 Jul 13;63(1):94-100. doi: 10.1212/01.wnl.0000133114.92694.93. Neurology. 2004. PMID: 15249617

6

Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice.

Schoonenboom NS, Mulder C, Vanderstichele H, Van Elk EJ, Kok A, Van Kamp GJ, Scheltens P, Blankenstein MA. Schoonenboom NS, et al. Among authors: scheltens p. Clin Chem. 2005 Jan;51(1):189-95. doi: 10.1373/clinchem.2004.039735. Epub 2004 Nov 11. Clin Chem. 2005. PMID: 15539465

7

Challenging the cholinergic system in mild cognitive impairment: a pharmacological fMRI study.

Goekoop R, Rombouts SA, Jonker C, Hibbel A, Knol DL, Truyen L, Barkhof F, Scheltens P. Goekoop R, et al. Among authors: scheltens p. Neuroimage. 2004 Dec;23(4):1450-9. doi: 10.1016/j.neuroimage.2004.08.006. Neuroimage. 2004. PMID: 15589109 Clinical Trial.

8

Medial temporal lobe atrophy and APOE genotype do not predict cognitive improvement upon treatment with rivastigmine in Alzheimer's disease patients.

Visser PJ, Scheltens P, Pelgrim E, Verhey FR; Dutch ENA-NL-01 Study Group. Visser PJ, et al. Among authors: scheltens p. Dement Geriatr Cogn Disord. 2005;19(2-3):126-33. doi: 10.1159/000082883. Epub 2004 Dec 23. Dement Geriatr Cogn Disord. 2005. PMID: 15627759

9

Amyloid beta 38, 40, and 42 species in cerebrospinal fluid: more of the same?

Schoonenboom NS, Mulder C, Van Kamp GJ, Mehta SP, Scheltens P, Blankenstein MA, Mehta PD. Schoonenboom NS, et al. Among authors: scheltens p. Ann Neurol. 2005 Jul;58(1):139-42. doi: 10.1002/ana.20508. Ann Neurol. 2005. PMID: 15984010

10

Cerebrospinal fluid tau levels in frontotemporal dementia.

Verbeek MM, Pijnenburg YA, Schoonenboom NS, Kremer BP, Scheltens P. Verbeek MM, et al. Among authors: scheltens p. Ann Neurol. 2005 Oct;58(4):656-7; author reply 657. doi: 10.1002/ana.20642. Ann Neurol. 2005. PMID: 16178027 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,253 results

Search Page